Literature DB >> 25691004

Cohort-Based Identification of Predictors of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis.

David Asuzu1, Karin Nyström2, Hardik Amin2, Joseph Schindler3,2, Charles Wira3,2, David Greer3,2, Nai Fang Chi4, Janet Halliday2, Kevin N Sheth5,6.   

Abstract

INTRODUCTION: Symptomatic intracranial hemorrhage (sICH) is a serious complication of IV rt-PA therapy after acute ischemic stroke. Independent sICH predictors have been previously derived using case-control studies. Here we utilized a novel cohort-based comparison to identify additional independent predictors of sICH.
METHODS: We included 210 patients receiving IV rt-PA therapy from January 2009 through December 2013 at the Yale-New Haven Stroke Center. Clinical parameters were compared using Mann-Whitney tests, two-sample tests of proportions and two-sample t tests. Logistic regression was performed using sICH as the dependent variable. Predictive ability was assessed using areas under the receiver operating characteristic (ROC) curve.
RESULTS: sICH rates were lowest from 2010 to 2012 and comprised the low sICH cohort (2.0 % sICH), compared to the high sICH cohort from 2009 to 2013 (9.2 % sICH, P = 0.025). Patients in the low sICH cohort had significantly more visual field deficits (38.6 vs. 24.8 %, P = 0.03) and decreased levels of consciousness (62.4 vs. 39.4 %, P < 0.001), but fewer hyperdense MCA signs (5 vs. 13.8 %, P = 0.03) and early CT hypodensities (14.9 vs. 29.4 %, P = 0.01). These four parameters together predicted sICH modestly (area under ROC curve 0.66, odds ratio 2.72, P = 0.03)
CONCLUSIONS: Using a novel cohort-based approach, we identified two new independent predictors of sICH after IV rt-PA therapy: the presence of the hyperdense MCA sign and early CT hypodensities. Novel methods are needed to reduce the risk of sICH for patients receiving antithrombolytic therapy for ischemic stroke.

Entities:  

Keywords:  IV Thrombolysis; Intracerebral hemorrhage; Neurocritical care

Mesh:

Substances:

Year:  2015        PMID: 25691004     DOI: 10.1007/s12028-015-0121-1

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  39 in total

1.  Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator.

Authors:  Patrick Lyden
Journal:  Stroke       Date:  2003-02-20       Impact factor: 7.914

2.  Early major ischemic changes on computed tomography should preclude use of tissue plasminogen activator.

Authors:  Rudiger von Kummer
Journal:  Stroke       Date:  2003-02-20       Impact factor: 7.914

Review 3.  Observational research methods. Research design II: cohort, cross sectional, and case-control studies.

Authors:  C J Mann
Journal:  Emerg Med J       Date:  2003-01       Impact factor: 2.740

4.  Estimability and estimation in case-referent studies.

Authors:  O Miettinen
Journal:  Am J Epidemiol       Date:  1976-02       Impact factor: 4.897

5.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

6.  The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.

Authors:  David M Kent; Harry P Selker; Robin Ruthazer; Erich Bluhmki; Werner Hacke
Journal:  Stroke       Date:  2006-10-26       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.

Authors:  Timothy John Ingall; William Michael O'Fallon; Kjell Asplund; Lewis Robert Goldfrank; Vicki S Hertzberg; Thomas Arthur Louis; Teresa J Hengy Christianson
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

9.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

10.  Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis.

Authors:  David Asuzu; Karin Nystrom; Hardik Amin; Joseph Schindler; Charles Wira; David Greer; Nai Fang Chi; Janet Halliday; Kevin N Sheth
Journal:  Neurocrit Care       Date:  2015-04       Impact factor: 3.210

View more
  3 in total

1.  TURN Score Predicts 90-day Outcome in Acute Ischemic Stroke Patients After IV Thrombolysis.

Authors:  David Asuzu; Karin Nyström; Joseph Schindler; Charles Wira; David Greer; Janet Halliday; Kevin N Sheth
Journal:  Neurocrit Care       Date:  2015-10       Impact factor: 3.210

2.  Predictors for Intracranial Hemorrhage Following Intravenous Thrombolysis in Posterior Circulation Stroke.

Authors:  Tomáš Dorňák; Michal Král; Zuzana Sedláčková; Daniel Šaňák; Eva Čecháková; Petra Divišová; Jana Zapletalová; Petr Kaňovský
Journal:  Transl Stroke Res       Date:  2018-01-15       Impact factor: 6.829

3.  TURN Score Predicts 24-Hour Cerebral Edema After IV Thrombolysis.

Authors:  David Asuzu; Karin Nyström; Anirudh Sreekrishnan; Joseph Schindler; Charles Wira; David Greer; Janet Halliday; W Taylor Kimberly; Kevin N Sheth
Journal:  Neurocrit Care       Date:  2016-06       Impact factor: 3.210

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.